Xenazine — CareFirst (Caremark)

Initial criteria

• Authorization of 6 months may be granted for the treatment of hemiballismus.

Reauthorization criteria

• Member is experiencing benefit from therapy as evidenced by disease stability or disease improvement.

Approval duration

Initial: 6 months; Reauthorization: 12 months